[HTML][HTML] Sex differences in immunity: implications for the development of novel vaccines against emerging pathogens
A Fathi, MM Addo, C Dahlke - Frontiers in immunology, 2021 - frontiersin.org
Vaccines are one of the greatest public health achievements and have saved millions of
lives. They represent a key countermeasure to limit epidemics caused by emerging infectious …
lives. They represent a key countermeasure to limit epidemics caused by emerging infectious …
Scent dog identification of samples from COVID-19 patients–a pilot study
…, V Pilchová, I Pink, T Welte, MP Manns, A Fathi… - BMC infectious …, 2020 - Springer
Background As the COVID-19 pandemic continues to spread, early, ideally real-time,
identification of SARS-CoV-2 infected individuals is pivotal in interrupting infection chains. Volatile …
identification of SARS-CoV-2 infected individuals is pivotal in interrupting infection chains. Volatile …
SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients
…, PM Duengelhoef, F Haag, TT Brehm, A Fathi… - Clinical …, 2022 - Elsevier
Background & Aims Detailed information on the immune response after second vaccination
of cirrhotic patients and liver transplant (LT) recipients against severe acute respiratory …
of cirrhotic patients and liver transplant (LT) recipients against severe acute respiratory …
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
T Koch, C Dahlke, A Fathi, A Kupke… - The Lancet Infectious …, 2020 - thelancet.com
Background The Middle East respiratory syndrome coronavirus (MERS-CoV) causes a
respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public …
respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public …
Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens
A Fathi, C Dahlke, MM Addo - Human vaccines & …, 2019 - Taylor & Francis
The devastating Ebola virus (EBOV) outbreak in West Africa in 2013–2016 has flagged the
need for the timely development of vaccines for high-threat pathogens. To be better prepared …
need for the timely development of vaccines for high-threat pathogens. To be better prepared …
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
A Fathi, C Dahlke, V Krähling, A Kupke… - Nature …, 2022 - nature.com
Vaccine development is essential for pandemic preparedness. We previously conducted a
Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East …
Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East …
Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73- Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes
…, S Kummer, S Schmiedel, JH Bockmann, A Fathi… - Cells, 2020 - mdpi.com
The ectonucleotidases CD39 and CD73 regulate immune responses by balancing extracellular
ATP and adenosine in inflammation and are likely to be involved in the pathophysiology …
ATP and adenosine in inflammation and are likely to be involved in the pathophysiology …
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity
…, M Ciurkiewicz, DL Shin, A Fathi… - The Journal of …, 2022 - Am Soc Clin Investig
The SARS-CoV-2 spike (S) glycoprotein is synthesized as a large precursor protein and must
be activated by proteolytic cleavage into S1 and S2. A recombinant modified vaccinia virus …
be activated by proteolytic cleavage into S1 and S2. A recombinant modified vaccinia virus …
[PDF][PDF] Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
LM Weskamm, A Fathi, MP Raadsen, AZ Mykytyn… - Cell Reports …, 2022 - cell.com
The Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS
coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of …
coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of …
Humoral and cellular immune response after third and fourth SARS-CoV-2 mRNA vaccination in liver transplant recipients
…, PM Duengelhoef, TT Brehm, H Karsten, A Fathi… - Clinical …, 2022 - Elsevier
… Brehm 1 2 , Hendrik Karsten 1 , Anahita Fathi 1 2 4 5 , Jacqueline Jahnke-Triankowski 6
7 , Lutz Fischer 6 7 , Marylyn M. Addo 1 2 4 5 , Friedrich Haag 3 , Marc Luetgehetmann 2 8 , …
7 , Lutz Fischer 6 7 , Marylyn M. Addo 1 2 4 5 , Friedrich Haag 3 , Marc Luetgehetmann 2 8 , …
